Pharmacological Debate Over Actos

In numerous cases nationwide, expert witnesses in pharmacology are being used to argue cases of a potential link between the prescription medication Actos and bladder cancer. One question that bears consideration is whether health benefits of the drug for some individuals outweigh its risks.

Actos as a Treatment

Actos (pioglitazone hydrochloride) is prescribed as a treatment of type 2 diabetes. The drug is not indicated for type 1 juvenile diabetes or diabetic ketoacidosis. According to the pharmaceutical manufacturer, Takeda Corporation, Actos prevents the liver from manufacturing unnecessary sugars while facilitating the body’s use of insulin to prevent sugars from building up in the bloodstream. The drug is contraindicated for people with certain heart ailments.

The Argument

Scientific studies have linked Actos to bladder cancer. In the United States, the Food and Drug Administration (FDA) has issued a safety warning to that effect and in France and Germany, the drug was taken off the market. When it comes to litigation, an expert witness in pharmacology is needed to testify whether an individual’s bladder cancer was caused by Actos or by other drugs or chemicals or by other factors.

Expert Witness in Pharmacology, Dr. Harry A. Milman

Dr. Harry A. Milman has a proven track record of effective testimony as an expert witness. He is an expert in pharmacology, toxicology, carcinogenesis, and pharmacy. If you have need for such an expert witness, please call Dr. Milman for a consultation at (301) 871-6715.

This entry was posted in Uncategorized. Bookmark the permalink.